Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellSpring Pharmaceutical Corp.

www.wellspringpharm.com

Latest From WellSpring Pharmaceutical Corp.

At Stannsoporfin Advisory Committee, Talk Of Additional Studies Stirs Feasibility Doubts And High Emotions

InfaCare’s jaundice drug needs more neurodevelopmental outcome studies, US FDA committee says, but one panelist doubts feasibility of long-term follow-up; talk of additional studies leads to an unusual tongue-lashing from one of InfaCare's experts, who says he was 'stunned' by the committee’s conclusion that efficacy had not been shown.

Advisory Committees Drug Approval Standards

Deals Shaping The Medical Industry, October 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.

BioPharmaceutical Medical Device

Industry News Roundup

Disclaimer alert symbol needed in ads; Prestige keeps Dramamine brand; DSM invests in omega-3s; Citizen petition to ban carrageenan withdrawn; NDAC to consider health care antiseptics; and Prolact CR cream supplement helps premature infants.

Consumer Advertising, Marketing & Sales

Industry News Roundup

Disclaimer alert symbol needed in ads; Prestige keeps Dramamine brand; DSM invests in omega-3s; Citizen petition to ban carrageenan withdrawn; NDAC to consider health care antiseptics; and Prolact CR cream supplement helps premature infants.

Consumer Advertising, Marketing & Sales
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • WellSpring Pharmaceutical Corp.
  • Senior Management
  • Robert A Vukovich, Chmn., Pres. & CEO
  • Contact Info
  • WellSpring Pharmaceutical Corp.
    Phone: (941) 312-4727
    5911 North Honore Ave., Ste. 2100
    Sarasota, FL 34243
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register